Search

Author/Creator Lares, A.

1. A PHASE II TRIAL OF REDUCED DOSE BRENTUXIMAB VEDOTIN FOR CUTANEOUS T‐CELL LYMPHOMAS. (17th June 2021)

Authors:
Khan, N.; Noor, S.; Geller, S.; Khodadoust, M. S.; Kheterpal, M.; Hancock, H.; Davey, T.; Ryu, S.; Perez, L.; Lares, A.; Ganesan, N.; Sohail, S.; Santarosa, A.; Galasso, N.; Kim, E.; Myskowski, P.; Kim, Y. H.; Horwitz, S.; Moskowitz, A.
Journal:
Hematological oncology
Issue:
Volume 39(2021)Supplement 2
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Clinical Grade Manufacturing of Human Alloantigen‐Reactive Regulatory T Cells for Use in Transplantation. Issue 11 (18th September 2013)

Authors:
Putnam, A. L.; Safinia, N.; Medvec, A.; Laszkowska, M.; Wray, M.; Mintz, M. A.; Trotta, E.; Szot, G. L.; Liu, W.; Lares, A.; Lee, K.; Laing, A.; Lechler, R. I.; Riley, J. L.; Bluestone, J. A.; Lombardi, G.; Tang, Q.
Journal:
American journal of transplantation
Issue:
Volume 13:Issue 11(2013)
Page Start:
3010
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗